Investigational drug · Phase 2
iPSC
Also called: human allogeneic induced pluripotent stem cell -derived dopaminergic neural progenitor cell, Allogeneic Human Induced Pluripotent Stem Cell -Derived Motor Neuron Progenitor Cells
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Spinal Cord Injury, Safety, Efficacy.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
85
Any phase or sponsor naming "iPSC"
First trial start
2025
Aug 5, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "iPSC", any sponsor or status.
Conditions studied
As listed on its trial records.
- Spinal Cord Injury
- Safety
- Efficacy
- Clinical Trial
- Induced Pluripotent Stem Cells
- Human Motor Neuron Progenitor
- Transplantation
- RCT
- Parkinson Disease (PD)
- Parkinson's Disease
Approved drugs for the same conditions: Parkinson's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "iPSC" as an intervention, largest first.
- Deployment and Evaluation of Humanoid Robotics in Coalition-Aligned Clinical Care SettingsPivotal-lookingEnrolling by invitation
Truway Health, Inc.Industry
NCT07214896 · 400 participants (planned) · Start Oct 6, 2025 · Primary completion Oct 6, 2031
Drug: Skin Cell Dip; Stem Cell Dip · For: Mobility Impairment; Clinical Workflow Optimization; Sanitation Protocol Compliance and 1 more
Sites: New York, New York; Austin, Texas; Frankfurt, Germany · 4 sites in all
University Hospital, BordeauxAcademic, hospital or other
NCT04122742 · 154 participants (planned) · Start Oct 8, 2019 · Primary completion Oct 2025
Drug: Culture of lymphoblastoid line from blood sample · For: Rubinstein-Taybi Syndrome
Sites: Talence, France
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
NCT05890781 · 108 participants (planned) · Start May 12, 2023 · Primary completion May 2028
Drug: Blood sample · For: Brain Tumor; Kidney Tumor; Neuroblastoma and 1 more
Sites: Villejuif, France; Paris, France
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.Industry
NCT07166757 · 90 participants (planned) · Start Sep 22, 2025 · Primary completion Mar 30, 2028
Drug: human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection · For: Parkinson Disease (PD)
Sites: Shanghai, China
- A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV)Pivotal-lookingRecruiting
HELP Therapeutics Co., Ltd.Industry
NCT07496372 · 80 participants (planned) · Start Apr 30, 2026 · Primary completion Jun 30, 2027
Drug: HiCM-188 therapy · For: Heart Failure
Sites: Tianjin, China
Charite University, Berlin, GermanyAcademic, hospital or other
NCT06967831 · 80 participants (planned) · Start Mar 1, 2020 · Primary completion Feb 28, 2030
Drug: off-label compassionate drug use · For: Leigh Syndrome (Maternally Inherited, MILS); Leigh Syndrome (AR, AD, XR)
Sites: Düsseldorf, Germany; Berlin, Germany
Cynata Therapeutics LimitedIndustry
NCT05643638 · 65 participants · Start Mar 4, 2024 · Primary completion Mar 17, 2026
Drug: CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs); Placebo and 1 more · For: Graft Versus Host Disease, Acute
Sites: Phoenix, Arizona; Little Rock, Arkansas; Jacksonville, Florida · 39 sites in all
- Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase II Randomized Controlled TrialNot yet recruiting
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.Industry
NCT06974968 · 60 participants (planned) · Start May 25, 2028 · Primary completion May 25, 2031
Drug: Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells · For: Spinal Cord Injury; Safety; Efficacy and 5 more
Sites: Guangzhou, China
- A Study of iMSC for the Prevention of Acute Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell TransplantationNot yet recruiting
Ruijin HospitalAcademic, hospital or other
NCT06949267 · 56 participants (planned) · Start Jun 1, 2025 · Primary completion Sep 30, 2026
Drug: iMSC · For: Acute Graft-versus-Host Disease
Eyestem Research Pvt. Ltd.Industry
NCT06394232 · 54 participants (planned) · Start Jun 4, 2024 · Primary completion Apr 2025
Drug: Eyecyte-RPE™ · For: Retinal Disease; Macular Degeneration; Age-Related Macular Degeneration and 2 more
Sites: Jālna, India; Delhi, India; Hyderabad, India
Newest research
PubMed records naming it or its code names, newest first.
- Corrigendum to "Dual human iPSC-derived cardiac lineage cell-seeding extracellular matrix patches promote regeneration and long-term repair of infarcted hearts" [Bioact. Mater. 28 (2023) 206-226].
Jiang Y, Zhang LL, Zhang F, et al. · Bioact Mater 2027
- Bupleuri Radix- Aurantii Fructus Immaturus pair attenuates metabolic dysfunction-associated fatty liver disease in association with modulation of PI3K/Akt-GSK3β/FoxO1 pathway: Evidence from multi-model validation including human iPSC-derived liver organoids.
Lu J, Li J, Yin P, et al. · J Ethnopharmacol 2027
- iPSC-derived cardiomyocytes for personalized medicine- promises and challenges.
Alagarsamy KN, Bueckert E, Gupta M, et al. · Biochim Biophys Acta Mol Basis Dis 2027
- Light-programmable gelatin hydrogels for bidirectional stiffness modulation and phase-specific tissue regeneration.
Tsai MC, Zhang SL, Chen KC, et al. · Biomaterials 2027
- Methods to Induce Differentiation of iPS Cells into Midbrain Organoids and Nigrostriatal Assembloids.
Yamaguchi A, Ishikawa KI, Akamatsu W · Methods Mol Biol 2027
- α-Synuclein Seeding Assay Using Dopaminergic Neurons from Induced Pluripotent Stem Cells.
Kitagawa M, Imoto M · Methods Mol Biol 2027
Also in development for Spinal Cord Injury
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.